Considerations of the discount rate in pharmacoeconomic evaluation in ChinaSUN Li-hua, ZONG Xin737-739
To establish adverse drug reactions damage compensation system in ChinaYANG Yue, JIANG Zhi-gang, LI Ye740-742,745
Related issues in phase 0 clinical trials in research and development of investigational new drugsYANG Zhi-min, SUN Tao, ZHAO De-heng743-745
Pharmacokinetics of geniposide through 4 routes of administrationYANG Ming, CHEN Xiao-yan, ZHANG Hai-yan, WANG Jian-min, LU Qian, SONG Wei746-749,754
Rationality of combination and proportion of cefotaxime/sulbactam in vitroLI Chang-qing, CHEN Wei, WANG Ting759-761
Genetic polymorphism of GNB3 C825T in association with efficacy of metoptololHAN Lu-lu, LI Na, JIANG Xiong-jing, LIU Yu-qing, LIU Hong, LI Yi-shi762-765,768
Comparison of the efficacy and safety of thrombolytic therapy using low dose reteplase and alteplase in patients over 75 years with acute myocardial infarctionZHANG Shuang-yue, WANG Xue-qing, LIU Chang-tao, BIAN Qiu-wu, MENG Xiao-jing, LIU Xiao-yuan766-768